Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002446 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients
A Phase 3 study, sponsored by Schering-Plough.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT00002446 is a Phase 3 study that has completed, run by Schering-Plough. The registered enrollment target is 300 participants.
The verdict
NCT00002446, a Phase 3 study, has completed, sponsored by Schering-Plough.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and effectiveness of 2 treatments for thrush (a fungal infection of the mouth and throat) in HIV-positive patients. Fluconazole is a drug that is commonly used to treat thrush. SCH 56592 is a new drug that will be compared to fluconazole.
Interventions
- DRUG Fluconazole
- DRUG Posaconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 1998-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002446
The ClinicalTrials.gov registry entry for NCT00002446 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Schering-Plough, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluconazole is the first listed.
NCT00002446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002446 about?
NCT00002446 is a clinical study titled "Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients". The purpose of this study is to compare the safety and effectiveness of 2 treatments for thrush (a fungal infection of the mouth and throat) in HIV-positive patients. Fluconazole is a drug that is commonly used to treat thrush. SCH 56592 is a new drug that will be compared to fluconazole.
What is the current status of trial NCT00002446?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 1998-08.
What interventions are being tested in trial NCT00002446?
The interventions under investigation include: Fluconazole (DRUG), Posaconazole (DRUG).
Who is sponsoring clinical trial NCT00002446?
This trial is sponsored by Schering-Plough, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.